Pipeline
The Best Target & The Best Chemical
FAK (Focal Adhesion kinase) plays an important role in signal transduction involved in cell migration, proliferation and differentiation by regulating cell growth and adhesion to extracellular matrix in normal and tumor cells. It is known that mutation of the FAK gene causes the loss of the interaction between the cell and the extracellular matrix, leading to metastasis of cancer cells. PHI-301 is a FAK inhibitor and is being developed as a drug to treat metastatic cancer by inhibiting abnormal signal transduction between cells and extracellular matrix.
-
68% of ovarian cancer
patients have FAK
overexpression -
The need for a therapeutic
agent with a mechanism that
inhibits the primary tumor in
the ovary from metastasis
to the peritoneum
through the EMT process.
Development of targeted therapy for metastatic ovarian cancer for patients with FAK overexpression
- Basic experiment result
-
-
-
Number of patients About 430,000 people
-
Market size KRW 1.5T (2023) Target Market
- Platinum-resistant/refractory ovarian cancer
- Patients with P53 mutation or EGFR overexpression
Sources : Ovarian cancer-Forecast: Datamonitor, Healthcare DMKC0177115